Ribobay Pharma, a prominent Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO), in conjuncti...
Innovent Biologics a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncol...
Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision...
Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...
Incyte and China Medical System Holdings Limited are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology m...
Snoring can be an alarming sign of obstructive sleep apnea syndrome (OSAS). Studies showed that 50% of individuals who snore may experience sleep apnea, wh...
— If approved, would confirm 2021 conditional approval and expand indication to more patients — HUTCHMED (China) Lim...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company focused on the development of novel antibody the...
Biotechnology Innovation Organization (BIO), a leading lobbying group in Washington, D.C., announced its decision to sever ties with WuXi AppTec, a Chinese...
Fujifilm Irvin Technology is a leader in the innovation and manufacturing of cell culture solutions in the global life sciences and medical markets. With t...
Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, an...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announces an antibody evaluation and option agreement with Gil...
Following the exercise of the Options and subject to receipt by HUTCHMED of ordinary shares representing approximately 7.5% of shares (fully diluted) in In...
© 2024 Biopharma Boardroom. All Rights Reserved.
